IRADIMED CORP (IRMD) Fundamental Analysis & Valuation

NASDAQ:IRMD • US46266A1097

Current stock price

95.6 USD
-0.94 (-0.97%)
Last:

This IRMD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

9

1. IRMD Profitability Analysis

1.1 Basic Checks

  • In the past year IRMD was profitable.
  • In the past year IRMD had a positive cash flow from operations.
  • In the past 5 years IRMD has always been profitable.
  • IRMD had a positive operating cash flow in each of the past 5 years.
IRMD Yearly Net Income VS EBIT VS OCF VS FCFIRMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M 10M 15M 20M 25M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 20.67%, IRMD belongs to the top of the industry, outperforming 98.94% of the companies in the same industry.
  • IRMD has a better Return On Equity (23.76%) than 96.28% of its industry peers.
  • IRMD has a Return On Invested Capital of 21.02%. This is amongst the best in the industry. IRMD outperforms 97.87% of its industry peers.
  • IRMD had an Average Return On Invested Capital over the past 3 years of 20.45%. This is significantly above the industry average of 9.36%.
  • The last Return On Invested Capital (21.02%) for IRMD is above the 3 year average (20.45%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 20.67%
ROE 23.76%
ROIC 21.02%
ROA(3y)19.63%
ROA(5y)17.03%
ROE(3y)23.33%
ROE(5y)20.07%
ROIC(3y)20.45%
ROIC(5y)17.53%
IRMD Yearly ROA, ROE, ROICIRMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 10 15 20 25

1.3 Margins

  • Looking at the Profit Margin, with a value of 26.82%, IRMD belongs to the top of the industry, outperforming 96.81% of the companies in the same industry.
  • In the last couple of years the Profit Margin of IRMD has grown nicely.
  • Looking at the Operating Margin, with a value of 31.20%, IRMD belongs to the top of the industry, outperforming 98.40% of the companies in the same industry.
  • IRMD's Operating Margin has improved in the last couple of years.
  • IRMD's Gross Margin of 76.75% is amongst the best of the industry. IRMD outperforms 88.30% of its industry peers.
  • In the last couple of years the Gross Margin of IRMD has remained more or less at the same level.
Industry RankSector Rank
OM 31.2%
PM (TTM) 26.82%
GM 76.75%
OM growth 3Y2.08%
OM growth 5YN/A
PM growth 3Y3.67%
PM growth 5Y44.08%
GM growth 3Y-0.3%
GM growth 5Y0.65%
IRMD Yearly Profit, Operating, Gross MarginsIRMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. IRMD Health Analysis

2.1 Basic Checks

  • IRMD has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • Compared to 1 year ago, IRMD has more shares outstanding
  • Compared to 5 years ago, IRMD has more shares outstanding
  • IRMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IRMD Yearly Shares OutstandingIRMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
IRMD Yearly Total Debt VS Total AssetsIRMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • An Altman-Z score of 55.46 indicates that IRMD is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 55.46, IRMD belongs to the top of the industry, outperforming 97.87% of the companies in the same industry.
  • IRMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 55.46
ROIC/WACC2
WACC10.53%
IRMD Yearly LT Debt VS Equity VS FCFIRMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.3 Liquidity

  • A Current Ratio of 7.98 indicates that IRMD has no problem at all paying its short term obligations.
  • IRMD has a Current ratio of 7.98. This is amongst the best in the industry. IRMD outperforms 88.30% of its industry peers.
  • IRMD has a Quick Ratio of 6.84. This indicates that IRMD is financially healthy and has no problem in meeting its short term obligations.
  • IRMD's Quick ratio of 6.84 is amongst the best of the industry. IRMD outperforms 88.83% of its industry peers.
Industry RankSector Rank
Current Ratio 7.98
Quick Ratio 6.84
IRMD Yearly Current Assets VS Current LiabilitesIRMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. IRMD Growth Analysis

3.1 Past

  • IRMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.36%, which is quite good.
  • The Earnings Per Share has been growing by 36.18% on average over the past years. This is a very strong growth
  • The Revenue has grown by 14.43% in the past year. This is quite good.
  • IRMD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.45% yearly.
EPS 1Y (TTM)16.36%
EPS 3Y20.77%
EPS 5Y36.18%
EPS Q2Q%22.73%
Revenue 1Y (TTM)14.43%
Revenue growth 3Y16.29%
Revenue growth 5Y21.45%
Sales Q2Q%17.03%

3.2 Future

  • Based on estimates for the next years, IRMD will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.02% on average per year.
  • IRMD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.59% yearly.
EPS Next Y10.5%
EPS Next 2Y11.02%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year11.27%
Revenue Next 2Y10.59%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
IRMD Yearly Revenue VS EstimatesIRMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
IRMD Yearly EPS VS EstimatesIRMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.5 1 1.5 2

More info and screens

Find the best growth stocksShow best growing peers

4

4. IRMD Valuation Analysis

4.1 Price/Earnings Ratio

  • IRMD is valuated quite expensively with a Price/Earnings ratio of 49.79.
  • Based on the Price/Earnings ratio, IRMD is valued a bit cheaper than 67.02% of the companies in the same industry.
  • IRMD is valuated expensively when we compare the Price/Earnings ratio to 25.51, which is the current average of the S&P500 Index.
  • Based on the Price/Forward Earnings ratio of 45.06, the valuation of IRMD can be described as expensive.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of IRMD indicates a somewhat cheap valuation: IRMD is cheaper than 67.55% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 22.76. IRMD is valued rather expensively when compared to this.
Industry RankSector Rank
PE 49.79
Fwd PE 45.06
IRMD Price Earnings VS Forward Price EarningsIRMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, IRMD is valued a bit cheaper than the industry average as 66.49% of the companies are valued more expensively.
  • 70.21% of the companies in the same industry are more expensive than IRMD, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 73.93
EV/EBITDA 43.3
IRMD Per share dataIRMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The excellent profitability rating of IRMD may justify a higher PE ratio.
PEG (NY)4.74
PEG (5Y)1.38
EPS Next 2Y11.02%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

3

5. IRMD Dividend Analysis

5.1 Amount

  • IRMD has a yearly dividend return of 0.72%, which is pretty low.
  • Compared to an average industry Dividend Yield of 0.24, IRMD pays a better dividend. On top of this IRMD pays more dividend than 90.96% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.89, IRMD's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.72%

5.2 History

  • IRMD has been paying a dividend for over 5 years, so it has already some track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
IRMD Yearly Dividends per shareIRMD Yearly Dividends per shareYearly Dividends per share 2022 2023 2024 2025 2026 0.5 1 1.5

5.3 Sustainability

  • 66.90% of the earnings are spent on dividend by IRMD. This is not a sustainable payout ratio.
DP66.9%
EPS Next 2Y11.02%
EPS Next 3YN/A
IRMD Yearly Income VS Free CF VS DividendIRMD Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
IRMD Dividend Payout.IRMD Dividend Payout, showing the Payout Ratio.IRMD Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

IRMD Fundamentals: All Metrics, Ratios and Statistics

IRADIMED CORP

NASDAQ:IRMD (4/2/2026, 12:22:34 PM)

95.6

-0.94 (-0.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-10
Earnings (Next)04-24
Inst Owners60.49%
Inst Owner Change3.31%
Ins Owners36.78%
Ins Owner Change-0.61%
Market Cap1.22B
Revenue(TTM)83.81M
Net Income(TTM)22.48M
Analysts82.5
Price Target122.4 (28.03%)
Short Float %6.07%
Short Ratio6.8
Dividend
Industry RankSector Rank
Dividend Yield 0.72%
Yearly Dividend1.18
Dividend Growth(5Y)N/A
DP66.9%
Div Incr Years0
Div Non Decr Years0
Ex-Date02-23
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.78%
Min EPS beat(2)1.27%
Max EPS beat(2)10.29%
EPS beat(4)4
Avg EPS beat(4)5.61%
Min EPS beat(4)0.43%
Max EPS beat(4)10.44%
EPS beat(8)7
Avg EPS beat(8)6.02%
EPS beat(12)10
Avg EPS beat(12)6.52%
EPS beat(16)14
Avg EPS beat(16)7.03%
Revenue beat(2)2
Avg Revenue beat(2)2.2%
Min Revenue beat(2)1.41%
Max Revenue beat(2)3%
Revenue beat(4)3
Avg Revenue beat(4)0.84%
Min Revenue beat(4)-1.05%
Max Revenue beat(4)3%
Revenue beat(8)4
Avg Revenue beat(8)0.28%
Revenue beat(12)7
Avg Revenue beat(12)0.4%
Revenue beat(16)7
Avg Revenue beat(16)0.02%
PT rev (1m)0%
PT rev (3m)21.21%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.26%
EPS NY rev (1m)-1.89%
EPS NY rev (3m)-1.89%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.52%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.02%
Valuation
Industry RankSector Rank
PE 49.79
Fwd PE 45.06
P/S 14.58
P/FCF 73.93
P/OCF 48.97
P/B 12.91
P/tB 13.39
EV/EBITDA 43.3
EPS(TTM)1.92
EY2.01%
EPS(NY)2.12
Fwd EY2.22%
FCF(TTM)1.29
FCFY1.35%
OCF(TTM)1.95
OCFY2.04%
SpS6.56
BVpS7.4
TBVpS7.14
PEG (NY)4.74
PEG (5Y)1.38
Graham Number17.88
Profitability
Industry RankSector Rank
ROA 20.67%
ROE 23.76%
ROCE 26.52%
ROIC 21.02%
ROICexc 43.68%
ROICexgc 47.04%
OM 31.2%
PM (TTM) 26.82%
GM 76.75%
FCFM 19.72%
ROA(3y)19.63%
ROA(5y)17.03%
ROE(3y)23.33%
ROE(5y)20.07%
ROIC(3y)20.45%
ROIC(5y)17.53%
ROICexc(3y)50.3%
ROICexc(5y)54.7%
ROICexgc(3y)54.98%
ROICexgc(5y)60.13%
ROCE(3y)25.8%
ROCE(5y)22.12%
ROICexgc growth 3Y-13.69%
ROICexgc growth 5YN/A
ROICexc growth 3Y-12.49%
ROICexc growth 5YN/A
OM growth 3Y2.08%
OM growth 5YN/A
PM growth 3Y3.67%
PM growth 5Y44.08%
GM growth 3Y-0.3%
GM growth 5Y0.65%
F-Score6
Asset Turnover0.77
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 722.21%
Cap/Sales 10.05%
Interest Coverage 250
Cash Conversion 91.34%
Profit Quality 73.51%
Current Ratio 7.98
Quick Ratio 6.84
Altman-Z 55.46
F-Score6
WACC10.53%
ROIC/WACC2
Cap/Depr(3y)948.96%
Cap/Depr(5y)635.99%
Cap/Sales(3y)11.43%
Cap/Sales(5y)7.92%
Profit Quality(3y)64.21%
Profit Quality(5y)73.8%
High Growth Momentum
Growth
EPS 1Y (TTM)16.36%
EPS 3Y20.77%
EPS 5Y36.18%
EPS Q2Q%22.73%
EPS Next Y10.5%
EPS Next 2Y11.02%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)14.43%
Revenue growth 3Y16.29%
Revenue growth 5Y21.45%
Sales Q2Q%17.03%
Revenue Next Year11.27%
Revenue Next 2Y10.59%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y19.04%
EBIT growth 3Y18.71%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1.68%
FCF growth 3Y26.52%
FCF growth 5Y26.12%
OCF growth 1Y-2.64%
OCF growth 3Y35.44%
OCF growth 5Y33.79%

IRADIMED CORP / IRMD Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for IRADIMED CORP?

ChartMill assigns a fundamental rating of 8 / 10 to IRMD.


Can you provide the valuation status for IRADIMED CORP?

ChartMill assigns a valuation rating of 4 / 10 to IRADIMED CORP (IRMD). This can be considered as Fairly Valued.


What is the profitability of IRMD stock?

IRADIMED CORP (IRMD) has a profitability rating of 9 / 10.


What is the earnings growth outlook for IRADIMED CORP?

The Earnings per Share (EPS) of IRADIMED CORP (IRMD) is expected to grow by 10.5% in the next year.


How sustainable is the dividend of IRADIMED CORP (IRMD) stock?

The dividend rating of IRADIMED CORP (IRMD) is 3 / 10 and the dividend payout ratio is 66.9%.